CTLA4 and lung carcinoma: conducted a meta-analysis of the potency of PD-1/CTLA-4 inhibitors in elderly individuals with lung cancer and showed that immunotherapy failed to prove that individuals ≥75 years old were statistically beneficial (HR Value 0.90; 95% CI, 0.64 to 1.25) (43).